BMJ should declare its own conflict of interest

Should benefit–risk assessment have its own drug “label”?

Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic implies that its benefits have been proven to exceed its harms. While the FDA could require proof that benefits exceed harms prior to approval, it has been argued that this approach would be infeasible because of prohibitively large sample sizes. One possible alternative w...

Conflict of evidence or conflict of interest?

We at EBSJ appreciate a substantial and mostly positive echo to the editorial titled “BMP: evidence in the name of science?” (EBSJ Volume 2, Issue 4). Thank you to all who have voiced their interest and support of our unique publication. Other publications have also echoed the desirability of a reevaluation of the methodology and conclusions of the article by Carragee et al titled: “A critical ...

Editorial interest in conflict of interest.

www.cmj.hr This year’s first issue of the Croatian Medical Journal (CMJ) did not feature only the new design of the journal (1) but also an update of its Guidelines for Authors (2), made regularly for each volume. We can only hope that our authors did notice the changes, as editorial experience and research evidence show that readers do not read journal documents (3) and that journals do not ke...

Will and Should the U.s. (and Europe) Declare (trade) War on China? the Political Economy of Trade Conflict

Globalization is taking hold of our imagination and of our scientific and political curiosity. Offshore outsourcing, Safeguard clauses against the import of Chinese textiles, anti-dumping measures against all other kinds of imports from the same origin, backlash against Chinese foreign direct investment (FDI) are the order of the day and, for some, shaking up trade theory. Should we worry about...

Advertisements in the BMJ. BMJ should not carry advertisements for cars.